Table 4. Top ranked up-regulated genes associated with poor prognosis.

Rank	Gene symbol	No. of specific references	Total no. of references	Total no. of platforms	Total no. of differentially expressed features	Gene name
1	BCL11A	3	5	4	19	B-cell CLL/lymphoma 11A (zinc finger protein)
2	TBXAS1	3	5	4	11	thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A)
3	HOXB5	2	9	5	32	homeobox B5
4	HOXA10	2	9	4	34	homeobox A10
5	CD34	2	9	3	16	CD34 molecule
6	RBPMS	2	8	4	21	RNA binding protein with multiple splicing
7	HOXA4	2	8	4	18	homeobox A4
8	MN1	2	8	4	16	meningioma (disrupted in balanced translocation) 1
9	GNAI1	2	6	3	12	guanine nucleotide binding protein (G protein), alpha inhibiting, activity polypeptide 1
10	SKAP2	2	5	4	21	src kinase associated phosphoprotein 2
11	MCM3	2	5	4	9	minichromosome maintenance complex component 3
12	CLIP2	2	5	3	8	CAP-GLY domain containing linker protein 2
13	DAPK1	2	5	3	8	death-associated protein kinase 1
14	GUCY1A3	2	4	4	8	guanylate cyclase 1, soluble, alpha 3
15	ANGPT1	2	4	3	11	angiopoietin 1
16	MTHFD1	2	4	3	6	methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase
17	MAP7	2	3	3	14	microtubule-associated protein 7
18	UGCGL2	2	3	3	11	UDP-glucose ceramide glucosyltransferase-like 2
19	SH2B3	2	3	3	6	SH2B adaptor protein 3
20	FLT3	2	3	3	5	fms-related tyrosine kinase 3

In order of preference, the genes are ranked by the number of poor prognosis related independent studies, the total number of independent studies, the total number of unique platforms, and the total number of features. Genes that were also associated with good prognosis with the same expression direction are not shown.